secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2025-08-22T23:59:59+00:00
Accession:  0001193125-25-186437
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics receives Nasdaq deficiency notice for equity below $2.5M minimum
--------------------------------------------------------------------------------

- Stockholders' equity as of June 30, 2025 was ~$1.6M, below the $2.5M continued listing requirement.
- Company has 45 calendar days (until October 4, 2025) to submit a plan to regain compliance to Nasdaq.
- If plan is accepted, Nasdaq may grant up to 180 additional calendar days to evidence compliance.
- Failure to regain compliance could lead to delisting; Company may appeal to a Nasdaq Hearings Panel.
- No immediate effect on listing or trading of common stock under symbol LYRA on Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000119312525186437/0001193125-25-186437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000119312525186437/d931635d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-186437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer